| 0.3914 0.011 (2.97%) | 08-21 11:01 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.46 | 1-year : | 0.54 |
| Resists | First : | 0.4 | Second : | 0.46 |
| Pivot price | 0.38  |
|||
| Supports | First : | 0.36 | Second : | 0.34 |
| MAs | MA(5) : | 0.38  |
MA(20) : | 0.37 |
| MA(100) : | 0.56 |
MA(250) : | 1.16 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 47.5 |
D(3) : | 61.5 |
| RSI | RSI(14): 47.8 |
|||
| 52-week | High : | 3.35 | Low : | 0.28 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ SNGX ] has closed above bottom band by 34.4%. Bollinger Bands are 94.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 41 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.39 - 0.39 | 0.39 - 0.39 |
| Low: | 0.37 - 0.38 | 0.38 - 0.38 |
| Close: | 0.38 - 0.38 | 0.38 - 0.38 |
Soligenix, Inc., a biopharmaceutical firm in its advanced development stages, concentrates on bringing innovative products to market within the United States, specifically targeting rare illnesses. The company's operations are divided into two main divisions: Specialized BioTherapeutics and Public Health Solutions. Within the Specialized BioTherapeutics division, Soligenix is advancing SGX301 (marketed as HyBryte), a novel photodynamic treatment that has successfully completed its Phase III clinical trials for managing cutaneous T-cell lymphoma. This segment also includes SGX942, an innate defense regulator technology currently undergoing Phase III trials for various inflammatory conditions, notably oral mucositis in patients with head and neck cancer. Additionally, this division is pursuing proprietary oral formulations of beclomethasone 17,21-dipropionate designed to prevent or treat severe inflammatory gastrointestinal disorders, such as SGX203 for pediatric Crohn's disease. Another candidate, SGX302, is currently in Phase I/II clinical development for addressing mild-to-moderate psoriasis. The Public Health Solutions segment is dedicated to developing several critical assets. These include RiVax, a vaccine candidate against ricin toxin, which has successfully completed Phase Ia and Ib clinical evaluations; SGX943, a therapeutic agent in pre-clinical studies aimed at combating antibiotic-resistant and emerging infectious diseases; ThermoVax, an early-stage technology focused on enhancing vaccine thermostability; and CiVax, a pre-clinical vaccine candidate intended for COVID-19 prevention. Soligenix, Inc. was originally established as DOR BioPharma, Inc. before adopting its current name in 2009. Founded in 1987, the company maintains its corporate headquarters in Princeton, New Jersey.
Thu, 20 Aug 2026
Soligenix (SNGX) Earnings Reading: The EPS Result Is Above Expectation in the Latest Session; Share Move - Vinanet
Fri, 07 Aug 2026
Soligenix Announces Recent Updates and Second Quarter 2026 Financial Results - PR Newswire
Mon, 03 Aug 2026
SOLIGENIX, INC. SEC Filing (Aug 3, 2026) - Stock Titan
Thu, 25 Jun 2026
SNGX Forecast — Price Target — Prediction for 2027 - TradingView
Wed, 27 May 2026
Soligenix more than doubles as traders react to Ebola-outbreak vaccine-platform update - Quiver Quantitative
Tue, 26 May 2026
SNGX - Finviz
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 15 (M) |
| Shares Float | 22 (M) |
| Held by Insiders | 4.5 (%) |
| Held by Institutions | 3.6 (%) |
| Shares Short | 483 (K) |
| Shares Short P.Month | 479 (K) |
| EPS | -1.46 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.28 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -84.9 % |
| Return on Equity (ttm) | -241.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.75 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -10 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | -0.27 |
| PEG Ratio | 0 |
| Price to Book value | 1.31 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.58 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|